Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(54)
•••
Comment by HarveyTwofaceon Apr 27, 2020 2:40pm
141 Views
Post# 30958765

RE:RE:RE:RE:RE:RE:silly question?

RE:RE:RE:RE:RE:RE:silly question?"stop expecting that"

Jeez, stop assuming I am expecting this. How did you come up with that?
I am pointing at an unknown variable that some seem to want to just ignore while trying to praise ATE as a safe bet.

yeah, might be close to a safe bet for this data readout, but far from as safe bet as some of you think when going into phase III. You all need to be more critical and stop with this fanboy nonsense.

We might cash in on upcoming news release, or maybe not. We are allowed to dream about market shares and things like that. But saying phase III is a walk in the park (like some say..) is just a way to not being truthful enough.

And with those words I'll leave the playground to you (until I'm back with more critical thoughts after the halt/NR).



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities